Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Momenta Pharmaceuticals Inc (MNTA)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Momenta's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
Momenta historical data, for real-time data please try another search
52.48 0.00    0.00%
30/09 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 52.46 - 52.53
Momenta 52.48 0.00 0.00%

Momenta Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Momenta Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
Industry
Sector
Employees

118

Equity Type

ORD

Momenta Pharmaceuticals, Inc., a biotechnology company, discovers and develops novel therapeutics for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy; and M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity. The company’s biosimilar programs comprise M923, a biosimilar of HUMIRA, for the treatment of patients with rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA, for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis as well as supporting the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. Momenta Pharmaceuticals, Inc. has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. Momenta Pharmaceuticals, Inc. was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. The company was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. Momenta Pharmaceuticals, Inc. operates as a subsidiary of Johnson & Johnson.

Contact Information

Address 301 Binney Street
Cambridge, 02142
United States
Phone 617 491 9700
Fax 617 621 0431
Web www.momentapharma.com
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

MNTA Comments

Write your thoughts about Momenta Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
ray dauria
ray dauria Sep 02, 2020 1:45AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
📉
Reply
0 0
Report
Red Or Green
Red Or Green Aug 19, 2020 12:15PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
So tomorrow a big drop?
Reply
4 0
Report
Joshua Carmichael
Joshua Carmichael Aug 19, 2020 12:15PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
no. JNJ acquired them for 6.5 mill. in a straight cash transaction.
Reply
1 0
Report
Uri Baro
Uri Baro Aug 19, 2020 11:21AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
what's has happened?
Reply
0 0
Report
Aug 19, 2020 11:08AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Acquired.
Reply
0 1
Report
Jack Lee
Jack Lee Jun 30, 2020 9:53AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Drop a lot?
Reply
1 0
Report
TRADERS INC
TRADERS INC Nov 10, 2019 3:41PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
157341834262121.jpg
Improving EPS and Revenues for MNTA. Nice looking up trend on the weekly, but must break through Resistance above closing price of $17 before i buy in. Looking at low 20's in the next few weeks if it breaks through.
Reply
1 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email